Coronavirus | Hyderabad CSIR lab helped develop key molecule for Covaxin
Updated:
Updated:
February 28, 2021 23:58 IST
Bharat Biotech had approached the Indian Institute of Chemical Technology to develop the synthetic route for the adjuvant molecule TLR 7/8 with indigenous chemicals at an affordable price and with highest purity.
Share Article
IICT chief S. Chandrasekhar with Bharat Biotech CMD Krishna Ella. Photo: Special Arrangement
Bharat Biotech had approached the Indian Institute of Chemical Technology to develop the synthetic route for the adjuvant molecule TLR 7/8 with indigenous chemicals at an affordable price and with highest purity. The Indian Institute of Chemical Technology (IICT), a Council for Scientific and Industrial Research (CSIR) lab here, played a role in the development of Covaxin, the indigenous vaccine developed by city-based Bharat Biotech International Limited.
URL copied
CSIR-IICT played key role in developing adjuvant for Covaxin, says CSIR
The process technology developed by the Council Of Scientific and Industrial ResearchâIndian Institute Of Chemical Technology for the agonist molecule is playing an important role in the production of adjuvant for Bharat Biotech s COVID-19 vaccine Covaxin, the CSIR said on Friday. The vaccine is formulated with Algel-IMDG, which contains chemisorbed TLR7/8 agonist onto aluminum hydroxide gel to generate the requisite type of immune responses, the CSIR said in a statement.
Owing to the significant role played by the TLR7/8 agonist molecule in the performance of a vaccine, the CSIR constituent lab, IICT based in Hyderabad, was approached by Bharat Biotech to develop the synthetic route for the agonist molecule with indigenous chemicals at an affordable price and with the highest purity.Â
IICT’s role in developing Covaxin of Bharat Biotech
February 26, 2021
×
Indian Institute of Chemical Technology (IICT) – CSIR has played a key role in developing Bharat Biotech’s Covid-19 vaccine, Covaxin.
Hyderabad-based IICT helped in the synthesis of Agonist molecules for use in Covaxin. It was approached by Bharat Biotech to develop the synthetic route for the agonist molecule with indigenous chemicals at an affordable price and with highest purity. This agonist molecule has aided in scaling up the production of the adjuvant, IICT said.
“The process technology developed by CSIR-IICT for the agonist molecule is playing an important role in the production of adjuvant for Covaxin,” said Shekhar Mande, DG, CSIR and Secretary, DSIR.
IICT aids Hyderabad start-up bag award thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Modelled on Hyderabad as a hub for over 40 research institutes
Finance Minister Nirmala Sitharaman has said that the Government proposes to create a formal umbrella like structure for research institutions across 9 cities in the country.
To promote innovation and research and development in the country, she said that a ‘Glue Grant’ will be set aside for this purpose which will create an umbrella like structure for R&D.
She said, “Many of our cities have various research institutions, universities, and colleges supported by the Government of India. Hyderabad for example, has about 40 such major institutions. In 9 such cities, we will create formal umbrella structures so that these institutions can have better synergy, while also retaining their internal autonomy.”